Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Association Between Maternal Intrapartum Pethidine Exposure and Respiratory Depression in Late-Preterm Newborns

14 de noviembre de 2026 actualizado por: Egyptian Chinese University

Association Between Maternal Intrapartum Pethidine Exposure and Neonatal Respiratory Depression in Late-Preterm Newborns: A Multicenter Prospective Cohort Study

This study aims to investigate whether exposure to pethidine during labor is associated with breathing difficulties in late-preterm newborns. Late-preterm babies are those born between 34 weeks and 36 weeks plus 6 days of pregnancy. Although they are close to full term, they may still have an increased risk of breathing problems after birth.

The study will be conducted at two hospitals: Zagazig University Hospitals in Egypt and Royale Hayat Hospital in Kuwait. It will include approximately 320 mothers and their newborn babies.

The researchers will prospectively observe two groups of mothers receiving combined spinal-epidural (CSE) analgesia during labor. The first group will include mothers who receive pethidine in addition to CSE analgesia as part of their clinical care. The second group will include mothers who receive CSE analgesia without pethidine. The decision to administer pethidine will remain entirely with the treating medical team and will not be determined by the research study.

The main purpose is to compare the occurrence of clinically significant breathing difficulties in newborns during the first 24 hours after birth. The study will also assess the need for newborn resuscitation, oxygen therapy, respiratory support, admission to the neonatal intensive care unit, feeding difficulties, and other neonatal outcomes. Maternal outcomes will also be evaluated.

The findings may improve understanding of the association between maternal intrapartum pethidine exposure and neonatal health, particularly when pethidine is used as an adjunct during labor to facilitate cervical effacement, ripening, and dilatation alongside combined spinal-epidural analgesia. The results may help clarify the potential neonatal respiratory risks associated with this practice, support evidence-based decisions regarding intrapartum pain management and cervical preparation, and contribute to improving maternal and neonatal safety.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Late-preterm infants, defined as newborns delivered between 34+0 and 36+6 weeks of gestation, have a higher risk of neonatal complications than term infants because of their relative physiological immaturity. Respiratory morbidity is particularly important in this population, as these newborns may experience respiratory difficulties requiring additional assessment, monitoring, or respiratory support after birth.

Pethidine (meperidine) is an opioid medication used in obstetric practice during labor. In addition to its analgesic properties, it may be administered as an adjunct during labor in certain clinical settings to facilitate cervical effacement and dilatation. Maternal intrapartum administration of pethidine results in placental transfer and fetal exposure. Because opioids can depress the central nervous system and respiratory drive, exposure close to delivery may potentially affect neonatal respiratory adaptation after birth.

The potential effects of maternal pethidine exposure are particularly relevant in late-preterm newborns, whose respiratory and neurological systems are not yet fully mature. However, the relationship between intrapartum pethidine exposure and clinically significant neonatal respiratory depression in this population requires further investigation, particularly in the context of contemporary obstetric analgesia practices.

This study will investigate the association between maternal intrapartum pethidine exposure and neonatal respiratory outcomes among late-preterm newborns delivered in two different clinical settings. The study will focus on mothers receiving combined epidural analgesia, comparing those who also receive pethidine as part of their routine clinical care with those who receive combined epidural analgesia without pethidine.

The research will follow a prospective observational cohort design. Maternal medication exposure and relevant obstetric characteristics will be documented, together with neonatal clinical assessments and outcomes. The administration of pethidine and the selection of analgesic techniques will remain entirely at the discretion of the treating obstetric and anesthetic teams. The research will not introduce, assign, or modify any medication or clinical intervention.

By examining the association between maternal pethidine exposure, obstetric characteristics, and neonatal outcomes, this study aims to provide clinically relevant evidence regarding the potential respiratory effects of intrapartum opioid exposure in late-preterm newborns. The findings may help inform evidence-based obstetric practices concerning the adjunctive use of pethidine during cervical effacement and dilatation, alongside maternal analgesia, while supporting appropriate neonatal monitoring and early recognition of respiratory complications.

Tipo de estudio

De observación

Inscripción (Estimado)

320

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 minuto a 1 día (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

late-preterm newborns delivered between 34+0 and 36+6 weeks of gestation. The study will include 320 newborns divided into two cohorts: 160 newborns exposed to maternal intrapartum pethidine alongside combined spinal-epidural analgesia and 160 newborns whose mothers received combined spinal-epidural analgesia without pethidine. Maternal clinical characteristics and intrapartum analgesic exposure will also be documented to assess their association with neonatal respiratory outcomes.

Descripción

Inclusion Criteria:

  1. Gestational age at delivery between 34+0 and 36+6 weeks.
  2. Maternal receipt of epidural analgesia during the index labor.
  3. Sufficient maternal medication and neonatal outcome documentation.

Exclusion Criteria:

  1. Congenital malformations expected to affect respiratory drive, airway patency, or cardiopulmonary adaptation
  2. Missing or unreliable maternal medication records that prevent exposure classification.
  3. Insufficient documentation to determine the primary outcome.
  4. Additional systemic opioid exposure that prevents meaningful classification according to the prespecified protocol.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Late-Preterm Newborns Exposed to Maternal Intrapartum Pethidine

160 late-preterm newborns (34+0 to 36+6 weeks of gestation) born to mothers who received intrapartum pethidine (meperidine), administered as part of routine clinical care at a planned dose of 50 mg administered via intramuscular (IM) or intravenous (IV) injection alongside combined spinal-epidural analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements.

Maternal intrapartum exposure to pethidine (meperidine), administered as part of routine clinical care at a planned dose of 50 mg administered via intramuscular (IM) or intravenous (IV) injection to facilitate cervical effacement and dilatation alongside combined spinal-epidural analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements. Pethidine administration is determined independently by the treating clinical team based on the mother's clinical condition and cervical assessment, and is not assigned or controlled by study investigators. The precise dose, route, cumulative amount, and timing/interval from administration to delivery will be prospectively documented to evaluate their association with neonatal respiratory outcomes in late-preterm newborns (34+0 to 36+6 weeks of gestation).

Otros nombres:
  • Meperidina
Late-Preterm Newborns Without Maternal Intrapartum Pethidine Exposure

160 late-preterm newborns (34+0 to 36+6 weeks of gestation) born to mothers who received combined spinal-epidural (CSE) analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements without intrapartum pethidine exposure.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Clinically Significant Neonatal Respiratory Depression Within 24 Hours After Birth
Periodo de tiempo: From birth through the first 24 hours of life

Clinically significant neonatal respiratory depression is defined as apnea, gasping, or inadequate respiratory effort requiring active resuscitation or respiratory intervention beyond routine initial newborn care. This includes the need for positive-pressure ventilation (PPV), or recurrent apnea or persistent inadequate respiratory effort requiring escalation of respiratory support.

The incidence will be calculated as the proportion of newborns experiencing at least one qualifying episode within the first 24 hours after birth. The association between maternal intrapartum pethidine exposure and this outcome will be assessed. Results will be reported as the number of affected newborns divided by the total number of newborns in each study group (n/N), and expressed as a percentage.

Unit of Measure: Number of participants (newborns) experiencing clinically significant neonatal respiratory depression.

From birth through the first 24 hours of life

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Neonatal Resuscitation at Birth
Periodo de tiempo: At birth, during initial neonatal resuscitation

The need for active neonatal resuscitation beyond routine initial newborn care will be recorded, including positive-pressure ventilation (PPV) and other advanced resuscitation interventions, if required. The proportion of newborns requiring resuscitation will be calculated for each study group.

Unit of Measurement: Number of participants (newborns) requiring active resuscitation.

At birth, during initial neonatal resuscitation
Need for Neonatal Respiratory Support
Periodo de tiempo: From birth through the first 24 hours of life

The requirement for respiratory support beyond routine initial newborn care will be recorded, including supplemental oxygen, continuous positive airway pressure (CPAP), non-invasive ventilation, and mechanical ventilation. The highest level of respiratory support required by each newborn during the assessment period will be documented.

Unit of Measurement: Number of participants (newborns) requiring respiratory support.

From birth through the first 24 hours of life
Association Between the Pethidine-to-Delivery Interval and Neonatal Respiratory Depression
Periodo de tiempo: From the maternal pethidine administration until delivery, with neonatal respiratory depression assessed from birth through the first 24 hours of life.

The association between the time interval from the maternal intrapartum pethidine administration to delivery and the occurrence of clinically significant neonatal respiratory depression will be evaluated. The interval will be calculated from the time of the last pethidine dose to the time of birth. The incidence of neonatal respiratory depression within the first 24 hours after birth will be analyzed in relation to this interval.

Unit of Measurement: Time interval (minutes or hours) between the maternal pethidine dose and delivery; number of newborns experiencing clinically significant respiratory depression.

From the maternal pethidine administration until delivery, with neonatal respiratory depression assessed from birth through the first 24 hours of life.
Apgar Scores
Periodo de tiempo: At 1 and 5 minutes after birth

Neonatal Apgar scores will be recorded at 1 and 5 minutes after birth. Each assessment will include heart rate, respiratory effort, muscle tone, reflex irritability, and skin color, with a total score ranging from 0 to 10 at each assessment.

Unit of Measurement: Apgar score (0-10).

At 1 and 5 minutes after birth
Neonatal Blood pH
Periodo de tiempo: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

Neonatal blood pH will be assessed using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal acid-base status. Results from both sampling time points will be recorded separately.

Unit of Measurement: pH (unitless).

At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
Neonatal Partial Pressure of Carbon Dioxide (PaCO₂)
Periodo de tiempo: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

Neonatal partial pressure of carbon dioxide (PaCO₂) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal ventilation status. Results from both sampling time points will be recorded separately.

Unit of Measurement: mmHg.

At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
Neonatal Partial Pressure of Oxygen (PaO₂)
Periodo de tiempo: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

Neonatal partial pressure of oxygen (PaO₂) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to assess neonatal oxygenation status. Results from both sampling time points will be recorded separately.

Unit of Measurement: mmHg.

At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
Neonatal Bicarbonate Concentration (HCO₃-)
Periodo de tiempo: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

Neonatal bicarbonate concentration (HCO₃-) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal metabolic acid-base status. Results from both sampling time points will be recorded separately.

Unit of Measurement: mmol/L.

At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
Neonatal Blood Lactate Concentration
Periodo de tiempo: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

Neonatal blood lactate concentration will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to assess metabolic status and identify evidence of tissue hypoperfusion. Results from both sampling time points will be recorded separately.

Unit of Measurement: mmol/L.

At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
Neonatal Lung Ultrasound Score
Periodo de tiempo: Within the first 24 hours after birth

Neonatal lung aeration will be assessed using a standardized six-region lung ultrasound examination. Each region will be scored from 0 to 3, producing a total lung ultrasound score ranging from 0 to 18, with higher scores indicating greater lung aeration impairment. Lung ultrasound findings will be evaluated to identify physiological transitional lung patterns and abnormalities suggestive of pulmonary pathology, including retained lung fluid and consolidation, helping to identify alternative or coexisting pulmonary causes of neonatal respiratory distress.

Unit of Measurement: Lung ultrasound score (0-18).

Within the first 24 hours after birth
Neonatal Feeding Difficulties
Periodo de tiempo: From birth through the first 24 hours of life

The occurrence of neonatal feeding difficulties will be assessed, including poor sucking, impaired coordination of sucking and swallowing, and feeding intolerance. The need for feeding assistance will also be documented. The proportion of newborns experiencing feeding difficulties will be calculated.

Unit of Measurement: Number of participants (newborns) experiencing feeding difficulties.

From birth through the first 24 hours of life
Neonatal Intensive Care Unit (NICU) Admission
Periodo de tiempo: From birth through the first 24 hours of life

The number and proportion of newborns requiring admission to the neonatal intensive care unit (NICU) will be recorded. The primary clinical indication for NICU admission, including respiratory or other neonatal complications, will be documented at the time of admission.

Unit of Measurement: Number of participants (newborns) admitted to the NICU.

From birth through the first 24 hours of life
Maternal Pain Intensity During Labour
Periodo de tiempo: Within the first 24 hours after delivery, covering the mother's overall experience of labour pain from the onset of labour until delivery.

Maternal pain intensity and the mother's overall experience of labour pain will be assessed in both study groups using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Each mother will be asked to provide an overall rating of the pain experienced during labour. The scores will be compared between the pethidine-exposed and unexposed groups.

Unit of Measurement: Numeric Rating Scale score (0-10).

Within the first 24 hours after delivery, covering the mother's overall experience of labour pain from the onset of labour until delivery.
Duration of Active Labour and Labour Progression
Periodo de tiempo: From pethidine administration until delivery

The duration of active labour following intrapartum pethidine administration will be assessed from the time of pethidine administration until delivery. Labour progression will be evaluated by documenting cervical dilatation (cm) and cervical effacement (%) at subsequent obstetric examinations following pethidine administration until delivery. The association between maternal pethidine exposure and labour progression will be assessed.

Unit of Measurement: Time from pethidine administration to delivery (hours); cervical dilatation (cm); cervical effacement (%).

From pethidine administration until delivery
Maternal Adverse Effects Associated With Intrapartum Pethidine Exposure
Periodo de tiempo: From pethidine administration until delivery

The occurrence of maternal adverse effects associated with intrapartum pethidine administration will be monitored and documented. Potential adverse effects include nausea, vomiting, dizziness, sedation, pruritus, hypotension, and respiratory depression. The type, occurrence, and any required clinical management of adverse effects will be recorded. The incidence of maternal adverse effects will be compared between the pethidine-exposed and unexposed study groups.

Unit of Measurement: Number of participants experiencing at least one maternal adverse effect.

From pethidine administration until delivery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Silla de estudio: Dr. Noha Nassar, PhD, MSc, Faculty of Pharmacy, Cairo University, Egypt
  • Director de estudio: Dr. Sarah Nafea, PhD, MSc, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Egypt
  • Director de estudio: Dr. Mahmoud Negm, PhD, MBBS, Faculty of Medicine, Zagazig University
  • Director de estudio: Dr. Nora Abdel Rasheed, PhD, MSc, Faculty of Pharmacy, Cairo University, Egypt
  • Investigador principal: Mustafa Alfiki, MSc, PharmD, Faculty of Pharmacy, Cairo University, Egypt; Royale Hayat Hospital, Kuwait

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de abril de 2027

Finalización del estudio (Estimado)

1 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

8 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .